Causes and Consequences of Metabolic Acidosis in Patients after Kidney Transplantation by Ritter, Alexander & Mohebbi, Nilufar








Causes and Consequences of Metabolic Acidosis in Patients after Kidney
Transplantation
Ritter, Alexander ; Mohebbi, Nilufar
Abstract: BACKGROUND Metabolic acidosis (MA) is a common complication in kidney transplantation
(KTx). It is more prevalent in KTx than in CKD, and it occurs at higher glomerular filtration rates.
The pathophysiologic understanding of MA in KTx and its clinical impact has been highlighted by
few recent studies. However, no guidelines exist yet for the treatment of MA after KTx. SUMMARY
MA in KTx seems to share pathophysiologic mechanisms with CKD, such as impaired ammoniagenesis.
Additional kidney transplant-specific factors seem to alter not only the prevalence but also the phenotype
of MA, which typically shows features of renal tubular acidosis. There is evidence that calcineurin
inhibitors, immunological factors, process of donation, donor characteristics, and diet may contribute
to MA occurrence. According to several mainly observational studies, MA seems to play a role in
disturbed bone metabolism, cardiovascular morbidity, declining graft function, and mortality. A better
understanding of the pathophysiology and evidence from randomized controlled trials, in particular, are
needed to clarify the role of MA and the potential benefit of alkali treatment in KTx. Alkali therapy
might not only be beneficial but also cost effective and safe. Key Messages: MA seems to be associated
with several negative outcomes in KTx. A deeper understanding of the pathophysiology and clinical
consequences of MA in KTx is crucial. Clinical trials will have to determine the potential benefits of
alkali therapy.
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Introduction
Acid-base homeostasis is crucial for human life. It is maintained mainly by adaptation of 
respiration and the kidneys. Metabolic acidosis (MA) is an acid-base disorder defined by an 
increased hydrogen ion concentration in the serum, resulting in low blood pH paralleled by 
decreased serum bicarbonate.
MA is a well-recognized complication of CKD and defined by a serum bicarbonate concen-
tration <22 mmol/L according to the KDIGO guidelines [1]. By increasing acid excretion and 
ammoniagenesis, the kidneys counteract a decrease in serum bicarbonate concentration. 
However, as the glomerular filtration rate (GFR) declines, the prevalence of MA increases [2, 
3]. A recent meta-analysis of numerous CKD, general population, and high cardiovascular risk 
cohorts demonstrated a substantial number of patients presenting with MA. The prevalence 
of MA averaged from 12.2 to 17.9% in nondiabetic CKD stage G3 patients and from 26.9 to 
36.6% in CKD stage G4 patients according to the KDIGO classification [3].
Importantly, also in kidney transplant recipients (KTRs), high prevalences of MA – 
ranging from 12 to 58% – have been reported. However, compared to CKD cohorts with 
similar degrees of renal function impairment, MA appears to be consistently more prevalent 
and occurs at higher GFR levels after kidney transplantation (KTx) [4]. The underlying mech-
anisms are not fully elucidated yet but potentially attributed to additional transplant-specific 
factors.
Chronic MA in CKD is associated with increased mortality and morbidity, such as reduced 
mineral bone content, growth retardation in children, increased protein catabolism, muscle 
wasting, chronic inflammation, impaired insulin sensitivity and cardiac function [5–8]. 
Moreover, there is increasing evidence that chronic MA can lead to progression of CKD [9–
14]. In addition, alkalinizing therapies in CKD patients reduced the decline of GFR in several 
randomized controlled trials (RCTs) [15–21]. Consequently, the KDIGO guidelines suggest 
bicarbonate substitution in CKD patients if serum bicarbonate concentration is <22 mmol/L 
[1]. In contrast to CKD patients, only few retrospective studies have been published on the 
impact of MA on graft function and mortality in KTRs [22–26]. Thus, although the first 
description of MA after KTx was more than half a century ago, there is still a lack of guidelines 
on how to deal with chronic MA in KTRs [27]. This review aims to give an overview on the 
current knowledge about the pathophysiology and the evidence from clinical studies on 
chronic MA in KTRs.
Causes of MA after KTx
The kidneys play a key role in the regulation of the acid-base balance by reabsorption of 
filtered bicarbonate, regeneration of bicarbonate via ammoniagenesis, and acid excretion 
[28]. While some of the pathogenic mechanisms of chronic MA in KTRs are similar to those in 
CKD patients, others seem to be specific to KTx.
Mechanisms in CKD
The daily load of nonvolatile acids can be eliminated by the kidneys via ammoniagenesis 
in the proximal tubular cells and secretion of mainly ammonium by type A intercalated cells 
in the collecting duct. Progression of CKD is characterized by interstitial fibrosis and tubular 
atrophy. This loss of renal mass leads to an increased ammoniagenesis in the remaining 
nephrons to ensure adequate renal acid secretion [29–31]. Impaired ammoniagenesis and 
reduced excretion of nonvolatile acids into the urine have been shown to be the main mecha-
nisms of MA contributing to CKD progression [5, 32, 33]. Accordingly, key molecules required 
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for renal ammoniagenesis and ammonia excretion were found to be highly downregulated in 
a CKD rat model [34]. Interestingly, a recent analysis of patients of the NephroTest cohort 
with CKD stages G1–4 showed that renal acid excretion may already be diminished without 
a simultaneous reduction of venous total carbon dioxide (tCO2) and significantly correlates 
with estimated glomerular filtration rate (eGFR) decline [35]. Thus, it is possible that other 
parameters than serum bicarbonate concentration such as urinary ammonium excretion 
might serve as early markers of MA in CKD.
Furthermore, early animal studies demonstrated that the compensatory increase of 
ammoniagenesis in surviving nephrons leading to ammonium-dependent complement acti-
vation causes tubulointerstitial injury [30, 36]. In the last years, data from animal experi-
ments and clinical studies showed a pathogenic impact of endothelin, aldosterone, and angio-
tensin-II in the context of MA, contributing to tubulointerstitial injury and CKD progression 
[16, 17, 19, 37–39]. In line with these studies, an upregulation of genes of proinflammatory 
cytokines was reported from a gene expression analysis of Madin-Darby canine kidney cells 
exposed to acid stress, supporting the hypothesis that inflammation induced by acidosis 
could lead to renal fibrosis and decline of kidney function [40]. Taken together, impaired 
ammoniagenesis, ammonium-dependent complement activation, and ammonium-inde-
pendent factors such as endothelin, aldosterone, and angiotensin-II seem to be involved in 
the progression of CKD by MA.
Additional Features and Mechanisms Specific to KTx
As mentioned above, chronic MA already appears at higher eGFR levels in KTx patients 
than in the CKD population. This circumstance suggests that there are additional mecha-
nisms, which are specific for the transplant setting. In KTRs, the typical features of renal 
tubular acidosis (RTA) such as normal anion gap normo- or hyperchloremic MA are usually 
found, while in CKD-associated MA, reduced serum chloride levels and a normal or increased 
anion gap are common [4, 41]. Although the first case report of chronic MA in KTx published 
in 1967 showed impaired renal acid excretion with the features of a mixed proximal and 
distal RTA [27], distal RTA type I (classic RTA) and distal RTA type IV (hyperkalemic RTA) 
are the common types seen in the course of KTx [41]. However, proximal RTA type II – due to 
tubular injury and hyperparathyroidism – has also been reported early after transplantation 
[42, 43]. As the tubular damage and hyperparathyroidism resolve, RTA may diminish entirely 
within the first 6 months post transplantation [44–46].
Calcineurin Inhibitors
Calcineurin inhibitors (CNIs) seem to play an essential role in the prevalence of MA in 
KTRs. Since the 1980s, CNIs are a key component of long-term immunosuppressive regimen 
after organ transplantation. Several studies could demonstrate an association of CNIs with 
the occurrence of chronic MA, with some evidence that it occurs more frequently with tacro-
limus than cyclosporine A [22, 24, 41, 47, 48]. This effect seems to be dose dependent [49, 50]. 
Human and animal studies have shown that both cyclosporine A and tacrolimus may cause 
functional tubular damage [47, 51, 52]. The different molecular mechanisms that lead to an 
alteration of the tubular electrolyte transport causing RTA were characterized in animal 
experiments. Cyclosporine A seems to block the adaptation of type B intercalated cells in the 
distal tubule by inhibiting the peptidyl-prolyl cis-trans isomerase activity [51]. With intake of 
tacrolimus, the expression or cellular distribution of important acid-base transport proteins 
such as the vacuolar proton pump, the anion exchanger AE1, or the sodium bicarbonate 
carbonate cotransporter NBCe1 was altered [52]. In addition, the use of mycophenolate 
formulations, antibiotics, and other drugs may cause chronic diarrhea in some patients after 
transplantation and subsequently contribute to nonanion gap MA.
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Immunological Factors
RTA occurs in autoimmune diseases such as systemic lupus erythematosus or Sjogren’s 
syndrome. The immunological mechanisms of autoantibodies cross-reacting with interca-
lated cells and impairing their function have been reported in Sjogren’s syndrome [53]. Thus, 
immunological factors like rejections might also be associated with MA; however, there is no 
definitive proof yet and results are conflicting. Earlier studies suggested that hyperchloremic 
acidosis was an early sign of allograft rejection [54, 55]. Another publication reported on a 
KTR suffering from acute rejection accompanied by severe MA, which entirely resolved after 
rejection treatment. Histologic findings revealed a reduced immunoactivity of the vacuolar 
proton pump and AE 1 in intercalated cells of the collecting duct, postulating an immuno-
logical pathogenesis of the MA [56]. However, in a small biopsy study, lower expression of the 
vacuolar proton pump after transplantation was found independent of acute rejection 
episodes [57]. In addition, in larger studies, no associations of acute rejections and MA were 
detected [22, 24, 41, 58].
Donation and Donor
Donation and donor-associated factors may play a role in the development of chronic 
MA – in particular since the incidence of MA early after transplantation is highest – but there 
is a paucity of evidence so far [4]. Five studies found a higher percentage or an association 
of MA in KTRs after deceased donor KTx [4, 22–24, 58], while in three other studies, no asso-
ciation was found for donor type [41, 49, 58, 59]. Only one study reported on prolonged cold 
ischemia time and an association with MA 3 months after transplantation [24]. So far, no 
association with donor age [22, 24] or sex was identified [22]. To our knowledge, no results 
on the influence of donor kidney function on MA occurrence after transplantation have been 
published yet.
Dietary Factors
High dietary acid intake in combination with reduced acid excretion capacity of the graft 
could result in a higher prevalence of MA after KTx. A study comprising 707 KTRs analyzed 
the impact of diet on acid-base homeostasis. Dietary acid load was identified as a relevant 
component contributing to MA in KTRs, leading to an increased net acid excretion (NAE). 
High dietary acid intake in the form of animal protein as well as a low consumption of fruit 
and vegetables was associated with significant lower blood pH and serum bicarbonate levels. 
NAE was calculated from 24-h urine collections to assess the metabolic acid load [60]. Addi-
tionally, dietary acid load could also uncover an underlying incomplete RTA, a common 
subclinical tubular defect in KTRs.
Other Factors
The single kidney state with a higher blood flow and changes in chemical and electrical 
transtubular gradients might contribute to a reduced renal NAE not only in nephrectomized 
patients but also in KTRs [61].
Consequences of MA after KTx
The majority of the evidence about consequences of MA derives from experimental and 
clinical studies in the non-transplant CKD setting. However, we feel that there is a great need 
for more data and firm evidence in the transplant population, especially to give physicians 
guidance for treatment of this metabolic disorder. Table 1 gives an overview of existing 
clinical studies about MA in KTx.
796Kidney Blood Press Res 2020;45:792–801
Ritter/Mohebbi: Metabolic Acidosis after Kidney Transplantation
www.karger.com/kbr
© 2020 The Author(s). Published by S. Karger AG, BaselDOI: 10.1159/000510158
Bone Metabolism
Bone metabolism was the first condition that was investigated in KTRs with MA. An early 
study identified an association of MA (bicarbonate <21 mmol/L) with low bone mineral 
density (BMD) measured by dual-energy X-ray absorptiometry (DXA) [62]. An association of 
MA (bicarbonate <24 mmol/L) with serological biomarkers, such as calcium, phosphorus, 
Table 1. Overview of clinical studies on MA after KTx
Reference Study design N* Study duration/
follow-up




Heaf et al. [62] Cross-sectional 
analysis
125 na na BMD Yes




823 na na Serological biomarkers Yes
Brazier et al. [24] Cross-sectional 
analysis
914 na na Serological biomarkers, 













Keven et al. [58] Cross-sectional 
analysis
68 na na BMD None
Franke et al. [64] Prospective 
observational cohort 
study
389 Median follow-up  
3.4 years
na Growth Yes
Schulte et al. [26] Retrospective 
observational cohort 
study
4,741 Median follow-up not 
reported; endpoints 
reported at 5 years 
after KTx




Djamali et al. [23] Retrospective 
observational cohort 
study
2,128 Median follow-up  
4.0 years




Park et al. [22] Retrospective 
observational cohort 
study
2,318 Median follow-up 
62–64 months
na DCGF and mortality Yes
Djamali et al. [23] Retrospective 
observational cohort 
study
2,128 Median follow-up  
4.0 years
na CVEs and all-cause 
mortality
Yes
Brazier et al. [24] Retrospective 
observational cohort 
study
914 Median follow-up  
47 months
na Serological biomarkers, 
graft failure, death, and 
composite outcome
Yes
Wiegand et al. [25] Post hoc analysis 90 1 year na Correlation of 
bicarbonate and eGFR
Yes
Schulte et al. [26] Retrospective 
observational cohort 
study
4,741 Median follow-up not 
reported; endpoints 
reported at 5 years 
after KTx
na DCGF, mortality, and 
bone fractures
None
na, not applicable; BMD, bone mineral density; MA, metabolic acidosis; CVEs, cardiovascular events; DCGF, death-censored graft failure; 
KTx, kidney transplantation; eGFR, estimated glomerular filtration rate; RCT, randomized controlled trial. * Number of study patients.
797Kidney Blood Press Res 2020;45:792–801
Ritter/Mohebbi: Metabolic Acidosis after Kidney Transplantation
www.karger.com/kbr
© 2020 The Author(s). Published by S. Karger AG, BaselDOI: 10.1159/000510158
and intact parathyroid hormone, was identified in another cross-sectional analysis [48]. 
Recently, patients with MA (bicarbonate <22 mmol/L) from a large French cohort were 
analyzed according to arterial pH. In this study, acidemia was shown to be associated with 
altered mineral metabolism, including blood ionized calcium, phosphate, and FGF-23 [24]. 
However, by now, only one RCT has been performed in KTRs with MA looking at different 
aspects of bone quality – in particular bone histology [63]. Despite a small sample size, the 
study protocol was very elaborate, comprising bone biopsies and DXA besides measurements 
of multiple serological biomarkers. Thirty patients with serum bicarbonate <24 mmol/L 
were treated with either potassium citrate or potassium chloride for 1 year. After 1 year, the 
bone structure was better preserved in the group treated with potassium citrate than in the 
group with potassium chloride. According to bone tetracycline labeling and serological 
markers, more bone turnover was seen in the group with alkali treatment. However, no 
relevant changes in bone mineral density were detected. In another cross-sectional study, no 
significant differences were seen in DXA measurements between 36 KTRs with and a control 
group without RTA [58]. Interestingly, a prospective observational cohort study in a pediatric 
transplant population identified the degree of MA as a significant predictor of growth [64]. 
Another cohort study using German health insurance data and ICD (International Statistical 
Classification of Diseases and Related Health Problems) codes, which is discussed in detail 
below, did not find any significant differences in the incidence of bone fractures between 
KTRs without MA, with MA, and with bicarbonate treatment [26].
Cardiovascular Events
Coronary artery disease, congestive heart failure, and arrhythmia are common among 
KTRs and account for mortality in many patients. Since MA is associated with several risk 
factors for cardiovascular disease, a recent large retrospective observational cohort study 
investigated the association of MA at 1 year post transplantation with cardiovascular events 
(CVEs) – ischemia, arrhythmia, and heart failure – and all-cause mortality [23]. A tCO2 level 
<20 mEq/L was associated with an increased risk for CVEs compared to reference patients 
with a tCO2 level of 24.0–25.9 mEq/L with an adjusted hazard ratio of 2.0 (95% CI 1.29–3.10). 
Interestingly, this association was mainly driven by ischemic events. The investigators also 
identified an independent association of MA with all-cause mortality – adjusted hazard ratio 
1.43 (95% CI 1.02–2.02) in the case of tCO2 level <20 mEq/L compared to the reference group. 
Further evidence from RCTs with safety assessment is required to clarify the potential role of 
alkali treatment in this context. In addition, the impact of sodium load on CVEs should also be 
investigated when sodium is given as a cation included in the alkali formulation.
Graft Outcome and Mortality
Although several randomized studies in patients with CKD have demonstrated a positive 
effect of alkali therapy on CKD progression and mortality, these data are lacking in KTx. To 
date, only observational studies have been published investigating the association of MA with 
graft function and/or mortality. A large multicenter retrospective cohort study from South 
Korea was the first to examine the influence of MA on graft and patient survival involving 
2,318 adult KTRs with an average follow-up of 5 years [22]. The authors demonstrated that 
a tCO2 level <22 mmol/L at 3 months after KTx was associated with an increased risk of graft 
loss and death-censored graft failure. In a second model using tCO2 as a time-varying variable 
and adjusting for several confounding factors, the relationship between MA and graft outcome 
was even stronger. In addition, MA was associated with a significantly higher risk of mortality, 
confirming this finding of the study discussed above [23]. Of note, this result was independent 
of graft function. The lowest risks for graft outcome and mortality were shown for tCO2 levels 
of 24–28 mmol/L. These findings raise the question whether the arbitrary threshold of 22 
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mmol/L to define MA is appropriate in KTRs. However, the study population included a high 
percentage of living kidney donations (approximately 75%), and the low prevalence of MA in 
this relatively healthy transplant cohort may limit its generalizability. A French retrospective 
cohort study including 914 KTRs reported a negative association of arterial bicarbonate 
levels with allograft loss and death, while baseline pH levels showed no association [24]. The 
authors identified 20 and 19 mmol/L as optimal arterial blood bicarbonate threshold for 
prediction of allograft loss or death, respectively. Results from a post hoc analysis of an open 
label RCT at our center showed a positive correlation of serum bicarbonate with eGFR in the 
first year after transplantation, supporting the hypothesis of a potential role of MA on graft 
function [25]. Additionally, a retrospective analysis of 430 KTRs from our cohort with a mean 
observation time of 5 years demonstrated that higher serum bicarbonate levels were asso-
ciated with long-term graft and patient survival (unpublished data).
So far, there is only one retrospective cohort study on the influence of bicarbonate therapy 
on death-censored graft failure, bone fractures, and mortality [26]. A total of 4,741 KTRs were 
allocated to three groups – no acidosis, acidosis, or alkali therapy – according to health 
insurance codes during the first year after transplantation and were followed up thereafter. 
The authors found no association of MA with increased frequency of graft failure, death, or 
bone fractures. In contrast, they saw an increased incidence of graft failure in the group 
treated with sodium bicarbonate. However, the study has strong limitations, and the results 
must be interpreted very carefully. The main limitation is certainly the lack of granularity of 
the encoded health insurance data. Moreover, relevant parameters such as graft function and 
severity of MA were unknown to the researchers, which may lead to confounding. It is possible 
that patients with worse graft function and higher risk of graft failure were more likely to 
receive treatment. These conflicting results underline the unmet need for more evidence. 
Thus, the results of an ongoing multicenter, single-blinded RCT investigating the effect of 
sodium bicarbonate on graft function in KTRs with MA over 2 years will be crucial to move 
an important and evidence-based step forward on this issue [65].
Conclusion
MA seems to be more common in the kidney transplant population than in CKD patients. 
Besides mechanisms that have been described in CKD, additional transplant-specific factors 
play a role in the development of MA. There is increasing evidence that MA may have negative 
effects on different organ systems in KTRs, including graft function. However, results from 
the existing, mainly observational studies are conflicting. Since the underlying mechanisms 
of MA in renal transplant patients are only partially corresponding to CKD patients, specific 
studies in the transplant population are crucial to identify patients at increased risk for severe 
complications, such as allograft loss and death. In addition, RCTs on clinical outcomes 
including safety are still missing and strongly required for guidance of alkali therapy. Imple-
menting alkali treatment into the drug regimen of KTx patients with MA could be a safe and 
cost-effective therapy and may have the potential to preserve long-term graft function and 
patient survival.
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